 |
160 Products |  |
813 Diseases | | 160 Products |
|
1630 Trials |  |
78802 News |  |
| «12...903904905906907908909910911912913914915» |
- Nplate (romiplostim) / Amgen, Promacta (eltrombopag) / Novartis
Trial initiation date: Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=50, Recruiting, Sponsor: Roskilde County Hospital
Initiation date: Sep 2011 --> Mar 2012
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: Etanercept Plus UVB-311nm Phototherapy in Psoriasis (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=6, Completed, Sponsor: Medical University of Graz
Initiation date: Sep 2011 --> Mar 2012 N=17 --> 6
- Nplate (romiplostim) / Amgen, Promacta (eltrombopag) / Novartis
Enrollment open: Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=50, Recruiting, Sponsor: Roskilde County Hospital
N=17 --> 6 Not yet recruiting --> Recruiting
- Bexxar (iodine I 131 tositumomab) / GSK
Enrollment closed: Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 14, 2012
P2, N=25, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Etanercept Plus UVB-311nm Phototherapy in Psoriasis (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=6, Completed, Sponsor: Medical University of Graz
Completed --> Active, not recruiting Recruiting --> Completed
- trebananib (AMG 386) / Amgen
New P1 trial, Combination therapy: Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 13, 2012
P1, N=24, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Enrollment open: S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride (clinicaltrials.gov) - Mar 13, 2012
P=N/A, N=140, Recruiting, Sponsor: Southwest Oncology Group
Recruiting --> Completed Not yet recruiting --> Recruiting
- | trebananib (AMG 386) / Amgen
New P2 trial: AMG 386 and Abiraterone for Advanced Prostate Cancer (clinicaltrials.gov) - Mar 12, 2012
P2, N=88, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Marqibo (vincristine liposomal) / Servier, Aurobindo
Enrollment closed: Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma (clinicaltrials.gov) - Mar 12, 2012
P3, N=665, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- melphalan / Generic mfg., busulfan / Generic mfg., thiotepa / Generic mfg.
Enrollment change: Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 11, 2012
P2, N=37, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Active, not recruiting N=30 --> 37
- FP-1039 / Amgen
Trial withdrawal, Metastases: Study of FP-1039 in Subjects With Endometrial Cancers (clinicaltrials.gov) - Mar 7, 2012
P2, N=0, Withdrawn, Sponsor: Five Prime Therapeutics, Inc.
N=30 --> 37 Recruiting --> Withdrawn
- FP-1039 / Amgen
Enrollment change, Metastases: Study of FP-1039 in Subjects With Endometrial Cancers (clinicaltrials.gov) - Mar 7, 2012
P2, N=0, Withdrawn, Sponsor: Five Prime Therapeutics, Inc.
Recruiting --> Withdrawn N=10 --> 0
- Kepivance (palifermin) / SOBI, Amgen, peripheral blood stem cell transplantation / National Cancer Institute
Enrollment change: Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma (clinicaltrials.gov) - Mar 7, 2012
P1, N=38, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
N=10 --> 0 N=30 --> 38
- | Stivarga (regorafenib) / Bayer
New P2 trial: A study to assess if regorafenib when given in combination with standard chemotherapy (FOLFIRI) will result in increased survival, without the cancer getting worse, as compared to a non-active treatment (placebo) given in combination with standard chemotherapy (FOLFIRI). The study will be conducted in a sub-group of metastatic colorectal cancer patients who have failed on their 1st oxaliplatin containing chemotherapy regimen. (EUDRACT) - Mar 7, 2012
P2, N=240, Ongoing, Sponsor: The Irish Clinical Oncology Research Group
- Trial termination: T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Mar 6, 2012
P2, N=7, Terminated, Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
N=30 --> 38 Suspended --> Terminated; Due to insufficient research institution participation and patient enrollment
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia (clinicaltrials.gov) - Mar 6, 2012
P=N/A, N=3, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Suspended --> Terminated; Due to insufficient research institution participation and patient enrollment N=10 --> 3
- Enrollment change: T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Mar 6, 2012
P2, N=7, Terminated, Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
N=10 --> 3 N=38 --> 7
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, plerixafor / Generic mfg.
New P2 trial: Collection of Transplant Stem Cells for Plasma Cell Myeloma (clinicaltrials.gov) - Mar 6, 2012
P2, N=70, Recruiting, Sponsor: National Cancer Institute (NCI)
- ivabradine / Generic mfg.
New P2 trial: Effects of oral administration of ivabradine (7.5 mg bid) on post-ischaemic stunning induced by exercise stress in patients with coronary artery disease and exercise inducible ischaemia. Effetti della somministrazione orale di ivabradina (7.5 mg bid) sulla capacita' contrattile del muscolo cardiaco ( (EUDRACT) - Mar 6, 2012
P2, N=15, Ongoing, Sponsor: INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
- trebananib (AMG 386) / Amgen, Torisel (temsirolimus) / Pfizer
New P1 trial, Surgery, Metastases: Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 6, 2012
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Pilot Study of Etanercept (Enbrel) in Children With Fanconi Anemia (clinicaltrials.gov) - Mar 6, 2012
P=N/A, N=3, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
N=38 --> 7 Recruiting --> Completed
- Trial completion: T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Mar 6, 2012
P1, N=20, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed Recruiting --> Completed
- Prolia (denosumab) / Amgen
New P2 trial, Tumor cell: Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer (clinicaltrials.gov) - Mar 5, 2012
P2, N=45, Recruiting, Sponsor: Hope Rugo, MD
- ||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P1 trial: Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Filgrastim (G-CSF)Produced by Blausiegel Ind (clinicaltrials.gov) - Mar 5, 2012
P1, N=128, Not yet recruiting, Sponsor: L.A.L Clinica Pesquisa e Desenvolvimento Ltda.
- Vectibix (panitumumab) / Amgen
Enrollment closed: Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck (clinicaltrials.gov) - Mar 5, 2012
P1, N=44, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Recruiting --> Active, not recruiting
- measles vaccine / Generic mfg.
Trial termination: Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer (clinicaltrials.gov) - Mar 4, 2012
P2, N=73, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; low accrual
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab (clinicaltrials.gov) - Feb 29, 2012
P4, N=100, Recruiting, Sponsor: Amgen
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Gene therapy: FANCA: Gene Therapy for Fanconi Anemia (clinicaltrials.gov) - Feb 29, 2012
P1, N=10, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Terminated; low accrual Not yet recruiting --> Recruiting
- ||| Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Roche
Enrollment closed, Combination therapy: Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Feb 28, 2012
P1/2, N=59, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- MK-2578 (darbepoetin alfa biosimilar) / Merck (MSD)
Enrollment change: A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12) (clinicaltrials.gov) - Feb 27, 2012
P2, N=39, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting N=158 --> 39
- || Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
New P3 trial: Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling (clinicaltrials.gov) - Feb 22, 2012
P3, N=80, Recruiting, Sponsor: Seoul National University Bundang Hospital
- | Stivarga (regorafenib) / Bayer
New P3 trial, Metastases: CONSIGN: Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy (clinicaltrials.gov) - Feb 22, 2012
P3, N=0, Available, Sponsor: Bayer
- | Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
New P1/2 trial: Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma (clinicaltrials.gov) - Feb 22, 2012
P1/2, N=40, Completed, Sponsor: M.D. Anderson Cancer Center
- trebananib (AMG 386) / Amgen
New P1 trial: Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - Feb 21, 2012
P1, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment open: Functional Implications of TNF (clinicaltrials.gov) - Feb 21, 2012
P=N/A, N=100, Recruiting, Sponsor: National Institute of Environmental Health Sciences (NIEHS)
N=158 --> 39 Not yet recruiting --> Recruiting
- || Traficet-EN (vercirnon) / Amgen
New P3 trial: SHIELD-4: An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease (clinicaltrials.gov) - Feb 20, 2012
P3, N=255, Terminated, Sponsor: GlaxoSmithKline
- Ibrance (palbociclib) / Pfizer
New P2 trial: A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression (clinicaltrials.gov) - Feb 20, 2012
P2, N=30, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change, Metastases: High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer (clinicaltrials.gov) - Feb 18, 2012
P2, N=61, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting N=96 --> 61
- ||| Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Feb 18, 2012
P1/2, N=74, Active, not recruiting, Sponsor: North Central Cancer Treatment Group
N=96 --> 61 Recruiting --> Active, not recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer (clinicaltrials.gov) - Feb 18, 2012
P2, N=61, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Xtoro (finafloxacin) / Amgen
New P3 trial: Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa (clinicaltrials.gov) - Feb 16, 2012
P3, N=693, Completed, Sponsor: Alcon Research
- |||||||||| Xtoro (finafloxacin) / Amgen
New P3 trial: Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa (clinicaltrials.gov) - Feb 15, 2012
P3, N=589, Completed, Sponsor: Alcon Research
- |||| Uplizna (inebilizumab) / Mitsubishi Tanabe, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment open: A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Feb 15, 2012
P2, N=180, Recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Trial initiation date: Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab (clinicaltrials.gov) - Feb 14, 2012
P=N/A, N=40, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Initiation date: Jul 2011 --> Jan 2012
- |||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Trial completion, Combination therapy, Metastases: A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC). (clinicaltrials.gov) - Feb 14, 2012
P2, N=165, Completed, Sponsor: Hoffmann-La Roche
Initiation date: Jul 2011 --> Jan 2012 Active, not recruiting --> Completed
- || doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg., gemcitabine / Generic mfg.
New P3 trial, Surgery: GOG study : Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery (clinicaltrials.gov) - Feb 13, 2012
P3, N=216, Recruiting, Sponsor: Gynecologic Oncology Group
- Campath (alemtuzumab) / Sanofi, Kepivance (palifermin) / SOBI, Amgen
Enrollment closed: Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) (clinicaltrials.gov) - Feb 13, 2012
P0, N=20, Active, not recruiting, Sponsor: Columbia University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- fulranumab (AMG-403) / Amgen
Enrollment change, Monotherapy: A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis (clinicaltrials.gov) - Feb 12, 2012
P2, N=196, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Active, not recruiting N=300 --> 196
- |||| CCX354 / Amgen
Trial completion: CARAT-2: A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy (clinicaltrials.gov) - Feb 7, 2012
P2, N=159, Completed, Sponsor: ChemoCentryx
N=300 --> 196 Active, not recruiting --> Completed
- docetaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma (clinicaltrials.gov) - Feb 7, 2012
P2, N=54, Completed, Sponsor: Sarcoma Alliance for Research through Collaboration
Active, not recruiting --> Completed Active, not recruiting --> Completed